Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer.
The direct intracellular delivery of proteins, or active peptide domains, has, until recently, been difficult to achieve due primarily to the bioavailability barrier of the plasma membrane, which effectively prevents the uptake of macromolecules by limiting their passive entry. Traditional approaches to modulate protein function have largely relied on the serendipitous discovery of specific drugs and small molecules which could be delivered easily into the cell. However, the usefulness of these pharmacological agents is limited by their tissue distribution and unlike 'information-rich' macromolecules, they often suffer from poor target specificity, unwanted side-effects, and toxicity. Likewise, the development of molecular techniques, over the past several decades, for gene delivery and expression of proteins has provided for tremendous advances in our understanding of cellular processes but has been of surprisingly little benefit for the management of genetic disorders. Apart from these gains however, the transfer of genetic material into eukaryotic cells either using viral vectors or by non-viral mechanisms such as microinjection, electroporation, or chemical transfection remains problematic. Moreover, in vivo, gene therapy approaches relying on adenoviral vectors are associated with significant difficulties relating to a lack of target specificity and toxicity which have contributed to poor performance in several clinical trials. Remarkably, the recent identification of a particular group of proteins with enhanced ability to cross the plasma membrane in a receptor-independent fashion has led to the discovery of a class of protein domains with cell membrane penetrating properties. The fusion of these protein transduction domain peptide sequences with heterologous proteins is sufficient to cause their rapid transduction into a variety of different cells in a rapid, concentration-dependent manner. Moreover, this novel technique for protein and peptide delivery appears to circumvent many problems associated with DNA and drug based methods. This technique may represent the next paradigm in our ability to modulate cell function and offers a unique avenue for the treatment of disease.
Wadia
Jehangir S
JS
Howard Hughes Medical Institute, and Department of Cellular and Molecular Medicine, University of California San Diego School of Medicine, La Jolla, California 92093-0686, USA.
Dowdy
Steven F
SF
D000818:Animals; D002462:Cell Membrane / Q000378:metabolism / Q000502:physiology*; D015696:Gene Products, tat / Q000737:chemistry / Q000378:metabolism / Q000502:physiology; D015497:HIV-1; D006801:Humans; D009369:Neoplasms / Q000235:genetics / Q000628:therapy; D010455:Peptides / Q000378:metabolism* / Q000502:physiology; D021381:Protein Transport / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology; D014161:Transduction, Genetic; D054322:tat Gene Products, Human Immunodeficiency Virus
D015696:Gene Products, tat; D010455:Peptides; D054322:tat Gene Products, Human Immunodeficiency Virus